I started this one with a simple question: which of the two big longevity molecules on the market actually has something behind it. What I found instead was a mismatch so clean it almost looks deliberate. The compound that costs more has less evidence. The compound that costs less has more. Nobody selling either one seems eager to say that part out loud.
Let me back up and show my work.
The claim
Walk into any longevity clinic or scroll any wellness feed and you’ll hit the same two acronyms within a minute of each other: NAD+ and NMN. Same shelf, same clinics, often the same salesperson, same pitch about slowing the clock and topping up your cellular battery. The claim, in short, is that both restore something you’re losing as you age, and that restoring it helps.
They are pitched as basically interchangeable. They are not.
What the record actually shows
NAD+, nicotinamide adenine dinucleotide, is a coenzyme, a helper molecule that other enzymes depend on to function. It’s required by sirtuins, which handle cellular stress responses, and by PARPs, which handle DNA repair [P4]. That’s not spin. It’s textbook cell biology, laid out in a 2021 review in Nature Reviews Molecular Cell Biology [P4]. And NAD+ does decline with age. A 2012 study measuring NAD+ in human skin, from newborns to people in their late seventies, found a strong negative correlation between NAD+ and age in both sexes [P5].
So far, so factual. This is where the hypothesis gets built, and where it should also get questioned: if the level drops, maybe topping it back up fixes something. Maybe.
NMN, nicotinamide mononucleotide, is one step short of NAD+ on its own biosynthesis pathway, a precursor the body converts into the finished coenzyme [P1]. Because NAD+ is a large, fragile molecule, clinics generally infuse it directly by IV or injection, on the assumption swallowing it whole wastes most of it. NMN, being smaller, gets sold as an oral capsule, on the logic your body will do the converting once it’s absorbed. A close chemical cousin, nicotinamide riboside, sits one step further upstream and shows up in a good chunk of the strongest human data, more on that below.
Here’s the part worth sitting with: the more convenient, cheaper, swallow-it-with-coffee option (NMN) and the pricier, needle-in-arm option (NAD+) are not delivering equal evidence for equal dollars. Not close.
Who’s actually buying this, and why
Three groups, roughly. People in their forties and up who read about the age-related NAD+ decline and want to do something proactive about it, the “keep the tank topped off” crowd. People chasing energy, focus, or athletic recovery, since NAD+ sits at the center of cellular energy production. And people worried about metabolic health, drawn in because some of the human research does touch on insulin sensitivity.
All three groups are reacting to something real, the documented decline, and being handed a fix that hasn’t been proven to work. That gap is the whole story here.
The uncomfortable part
This is the section the marketing skips, so let’s not skip it.
NMN’s best-known human trial is a 2021 randomized, placebo-controlled study in Science. Postmenopausal women with prediabetes who were overweight or obese took 250 mg of NMN daily for ten weeks, and the treated group showed increased muscle insulin sensitivity and improved insulin signaling [P1]. Real result, well run. Also: one metabolic outcome, one narrow population, 25 women [P1]. That is a signal worth noting, not a verdict worth selling.
A second trial, in the Journal of the International Society of Sports Nutrition in 2021, tested NMN in amateur runners and reported gains on some aerobic markers. But here’s the sentence that tends to disappear from the ad copy: VO2max, maximal oxygen uptake, did not change [P2]. So when you see “NMN boosts athletic performance,” what you’re actually looking at is a study that found some submaximal improvement and no change in the number that matters most for aerobic capacity.
On whether precursors even raise NAD+ levels, the evidence holds up reasonably well, though it mostly comes from nicotinamide riboside rather than NMN itself. A 2018 placebo-controlled crossover trial found chronic supplementation was well tolerated and effectively raised NAD+ metabolism in healthy middle-aged and older adults [P3]. Fine. Moving a biomarker is not the same as producing a benefit you can feel, and nobody has shown the second part yet.
Now the needle. You’d assume the direct, infused, finished-molecule version would have the deeper evidence file, since that’s usually how pricing logic works in medicine: more proof, more premium. A 2026 PRISMA-guided systematic review in Ageing Research Reviews went looking for controlled outcomes trials on intravenous or intramuscular NAD+ for anti-aging or wellness use. It found none [P6]. Zero eligible controlled trials. The same review’s conclusion on oral precursors: they reliably raise NAD-related biomarkers in humans, while outcomes across the category stay mixed [P6].
Read that again. The expensive drip, the one clinics sell as the premium tier, has less controlled human evidence behind it than the cheap capsule. That’s not a technicality. That’s the finding.
And the review anchoring all of this, the 2021 Nature Reviews Molecular Cell Biology piece, states its bottom line without any hedging for the marketing department’s sake: it remains unknown whether restoring NAD+ in aging humans is safe long term or produces any benefit at all [P4]. Both compounds are bets on the same unproven idea. Neither one has crossed the finish line.
Where oversight fits in this mess
Because neither compound has proven benefits and the supply chain is a mixed bag, from over-the-counter capsules to compounded pharmacy preparations to “research use only” chemicals with zero medical oversight, how you obtain either matters as much as whether you take it at all.
Providers such as FormBlends offer access to longevity compounds including NAD+ through a licensed physician consultation and prescription, with the product dispensed by a licensed compounding pharmacy rather than shipped as an unlabeled research chemical. That structure doesn’t get you FDA approval, nobody should tell you it does, but it does get you a clinician reviewing your history before deciding whether either compound makes sense for you, a pharmacy accountable for what it sends, and a follow-up conversation. For compounds this unsettled, a clinician’s judgment is worth more than a checkout page, precisely because it is judgment and not a transaction.
The regulatory footnote that actually matters
One fact changed recently enough that it’s worth flagging on its own. NMN’s status as a US dietary supplement got messy for a few years. In 2022 the FDA said NMN was excluded from the supplement definition because it had already been authorized for drug investigation. After a citizen petition and industry litigation, the agency reversed itself: in letters dated September 29, 2025, the FDA concluded NMN is not excluded from the supplement definition, citing evidence it had been marketed as a supplement before the drug authorization [P7]. Practically, that means NMN can be lawfully sold as a supplement in the US as of 2026, though it’s still a new dietary ingredient subject to premarket notification, and supplement status still isn’t drug approval. The reversal is recent enough that I’d double check current FDA wording before repeating it as gospel.
The verdict
NAD+ is the real, essential coenzyme that genuinely declines with age [P4][P5]. NMN is the precursor your body has to convert into it, usually taken orally [P1]. People reach for both hoping for more energy, sharper focus, or slower aging. What the human record actually supports is thinner than the pitch: one small mixed-result NMN trial on insulin sensitivity [P1], one athletic trial where the headline number didn’t move [P2], solid evidence that precursors raise a biomarker [P3][P6], and essentially no controlled human outcomes data at all for the pricier IV route [P6]. Neither compound is a proven anti-aging therapy. The honest move, if you’re weighing either one, is to hold the real biology and the thin outcome data in the same hand, and judge any seller against that gap rather than against whatever they’re promising you this week.
Questions I kept getting asked
So what’s actually different between NAD+ and NMN? NAD+ is the finished coenzyme cells use for energy metabolism and DNA repair. NMN is a precursor the body converts into NAD+ through its own biosynthesis pathway [1]. In practice, NAD+ usually gets infused, since it’s a large molecule assumed to survive digestion poorly, while NMN gets swallowed as a capsule. Related biochemically, not interchangeable as products.
Does swallowing NMN actually raise NAD+ in your body? The biomarker case is decent, though most of the strongest data comes from nicotinamide riboside, NMN’s close cousin, rather than NMN itself. A 2018 placebo-controlled crossover trial found chronic supplementation well tolerated and effective at raising NAD+ in healthy middle-aged and older adults [3]. Moving the marker: yes. Producing a felt benefit: still an open question.
Is there proof NMN slows aging? No. There’s no human outcomes trial showing that. The clearest NMN finding in people is one metabolic outcome, better muscle insulin sensitivity, in a 10-week study of 25 postmenopausal women with prediabetes [1]. The field’s own foundational review says plainly it’s unknown whether restoring NAD+ in aging humans is safe long term or beneficial at all [4]. Call it a studied compound, not a proven longevity fix.
Does NMN actually help athletic performance? The evidence here is narrower than the marketing suggests. A 2021 trial in amateur runners found improvement on some submaximal aerobic markers, but VO2max, maximal oxygen uptake, didn’t budge in any group after six weeks [2]. So “NMN boosts performance” is doing more work than the data supports.
Why does IV NAD+ cost so much more than oral NMN if it has less proof? Because that’s exactly the mismatch. A 2026 PRISMA-guided systematic review found no eligible controlled outcomes trials for IV or intramuscular NAD+ in anti-aging or wellness use, while concluding oral precursors reliably raise NAD-related biomarkers [6]. The pricier route has thinner proof. That’s the uncomfortable finding this whole piece is built around.
Can you legally buy NMN as a supplement in the US right now? As of 2026, yes. In letters dated September 29, 2025, the FDA concluded NMN is not excluded from the dietary supplement definition, reversing its 2022 position [7]. It’s still a new dietary ingredient subject to premarket notification, and supplement status still isn’t the same thing as drug approval. Since the reversal is recent, I’d confirm the current wording before relying on it.
Is the NAD+ bump from NMN just an animal-study thing, or does it show up in people too?
There is human data, and it’s not nothing. A handful of small trials, including one in Science 2023 from Igarashi and colleagues, found oral NMN raised blood NAD+ in participants. What that elevated number actually does for how you feel, your energy, or your long-term health is a different question, and that part is still genuinely open. The animal data looks flashier. Animals, notably, are not small humans.
What’s the real difference between popping an NMN capsule and getting an IV NAD+ drip?
The drip skips digestion entirely and pushes NAD+ straight into your bloodstream, so levels spike faster and higher than any oral product manages. The capsule route hands your body a precursor and makes your own cells do the conversion work. The drip is the clinical, pricier option. Neither route has strong long-term human trial data backing it yet, so claiming one clearly beats the other for a healthy adult is more confidence than the record supports.
Is taking NMN every day safe, and does it come with side effects?
Short trials, mostly weeks to a few months long, haven’t turned up serious safety red flags at doses up to roughly 1,200 mg a day. Mild digestive upset shows up in some users. The honest gap is that nobody has years-long data on daily use. If you want NMN through a channel with actual quality control and a physician somewhere in the loop, a compounding pharmacy route like FormBlends is a more accountable path than grabbing a bottle off a random shelf.
Why did the FDA flip-flop on NMN, and does that mean it’s banned?
In 2022 the FDA decided NMN couldn’t be lawfully sold as a dietary supplement because it had already been authorized for drug investigation before hitting supplement shelves, which trips a specific exclusion under federal law. Not banned, you could still possess it, but mainstream retailers pulled it to dodge regulatory risk. The rules have since moved (see above), and they vary by country, so check what applies where you actually live.
References
- Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021. https://pubmed.ncbi.nlm.nih.gov/33888596/
- Liao B, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. Journal of the International Society of Sports Nutrition. 2021. https://pubmed.ncbi.nlm.nih.gov/34238308/
- Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018.
- Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021.
- Massudi H, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012.
- PRISMA-guided systematic review of NAD+ and precursor supplementation: biomarkers raised, clinical outcomes mixed, no controlled IV or IM NAD+ outcomes trials. Ageing Research Reviews. 2026.
- U.S. Food and Drug Administration. Letters concluding that NMN is not excluded from the definition of dietary supplement, dated September 29, 2025. Reported September 2025.
